Immunic IMUX Investor Presentation October 2023

Immunic develops a pipeline of next-generation selective oral therapies targeting chronic inflammatory and autoimmune diseases. The presentation outlines the company's strategy to deliver clinically meaningful treatment options to patients through its immunology-focused development programs, presented to investors in October 2023.